Anti-p53 antibody
Description
Application Data
Description
-
Recognises p53, a tumour suppressor and DNA binding protein that regulates transcription
Application Data
-
Anti-p53 antibody (crb2005216) (1μg/ml)
Western blot analysis of human embryonic kidney cells: HEK293
| Catalogue number | crb2005216 |
|---|---|
| Antibody | Anti-p53 antibody |
| Antigen Peptide | KLH conjugated synthetic peptide crb1200508e |
| Protein ID | UniProtKB - P04637 |
| Aliases | tumour protein p53, cellular tumour antigen p53, phosphoprotein p53, tumour suppressor p53, antigen NY-CO-13, transformation-related protein 53 (TRP53) |
| Cross-Reactivity | Human |
| Target Protein Species | Human |
| Host Species | Rabbit |
| Antibody Type | Polyclonal |
| Concentration | 0.1 mg/ml |
| Validation | 1:1000 (ELISA), 1:1000 (WB) |
| Target | p53 |
| Storage Stabilisers | This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles. |
| Disease Area | Cancer, DNA Damage, apoptosis, transcription, cell cycle, signal transduction |
| Specificity | Protein |
| Storage | This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles. |
| References | Cheok, C. and Lane, D. (2017). Exploiting the p53 Pathway for Therapy. Cold Spring Harb Perspect Med, 7(3), a026310. PMID: 28193768
Kastenhuber, E. and Lowe, S. (2017). Putting p53 in Context. Cell, 170(6), 1062-1078. PMID: 28886379 |
p53 is a sequence-specific DNA binding protein that regulates transcription. p53 is maintained at low levels in normal cells through mouse double minute 2 (MDM2) mediated degradation, however it is stabilised by phosphorylation and thus accumulates in response to cellular stresses such as DNA damage and replication stress. When p53 accumulates it promotes cell cycle arrest and apoptosis, thereby reducing the risk of propagating mutations. p53 mediates the DNA damage-induced G1 phase checkpoint, partly via its ability to transcriptionally activate the p21 cyclin-dependent kinase inhibitor gene. Activation of p21 triggers cell cycle arrest to allow for DNA repair prior to further cell division. p53 therefore acts as a tumour suppressor and inactivating mutations in the human p53 gene TP53 are common in many cancers.
